guidelines

Do International Model Drug Control Laws Provide for Drug Availability?

Citation:

Pain & Policy Studies Group. Do International Model Drug Control Laws Provide for Drug Availability? J Pain Palliat Care Pharmacother 2009;23:145-152.

Abstract:
Author: 

Pain & Policy Studies Group. Do International Model Drug Control Laws Provide for Drug Availability? J Pain Palliat Care Pharmacother 2009;23:145-152.

A preliminary review of the United Nations Office on Drugs and Crime (UNODC) model drug control laws was conducted by the Pain & Policy Studies Group (PPSG) to determine whether the models provided governments with language they can use to carry out the obligation to ensure adequate availability of opioid analgesics for the relief of pain and suffering, specified in the Single Convention on Narcotic Drugs, 1961 as amended, and as recommended by the International Narcotics Control Board in 1995. The results showed that current model laws lack the drug availability provisions.

Ensuring patient access to essential medicines while minimizing harmful use: A revised WHO tool to improve national drug control policy

Citation:

Gilson AM, Maurer MA, Ryan KM, Skemp-Brown M, Husain A, Cleary JF. Ensuring patient access to essential medicines while minimizing harmful use: A revised WHO tool to improve national drug control policy. J Pain Palliat Care Pharmacother 2011;25:246-251.

Abstract:
Author: 

Gilson AM, Maurer MA, Ryan KM, Skemp-Brown M, Husain A, Cleary JF. Ensuring patient access to essential medicines while minimizing harmful use: A revised WHO tool to improve national drug control policy. J Pain Palliat Care Pharmacother 2011;25:246-251.

In 2011, the World Health Organization (WHO) published a series of 21 guidelines to assist governments in improving their national drug control laws, regulations, and administrative procedures to promote the availability of controlled medicines for pain relief and for a variety of acute and chronic diseases and conditions. These guidelines ultimately are designed to encourage the development of policies designed to fulfill a country's dual obligation concerning these medicines: to prevent their abuse, diversion and trafficking while ensuring access for medical and scientific purposes.

Syndicate content